AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$XCUR

EXICURE, INC.

Price · $XCURvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $XCUR in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $XCUR in the last 30 days.

Top stories · $XCURMore →
APR 3·Stock TitanLow

Exicure (NASDAQ: XCUR) advances derivative case settlement with new governance controls

Exicure (NASDAQ: XCUR) has achieved preliminary court approval for a global settlement of stockholder derivative lawsuits related to past research data handling and corporate disclosures. The agreement requires Exicure to implement significant corporate governance reforms for at least four years, including creating a new board-level Research and Data Integrity Oversight Committee and a management-level Disclosure Committee. Defendants' insurers will cover $675,000 in plaintiffs' attorneys' fees, and a final court approval hearing is scheduled for June 2, 2026.

MAR 29·baoquankhu1.vn

Analyst Calls: Is Exicure Inc stock heavily shorted - Weekly Investment Recap & Daily Price Action Insights

The article prominently features repeated, generic calls to join a "Real-Time Stock Group" for smart investing and wealth building, interspersed with unrelated content about the second phase of Line 8 subway project, tourist attractions in Yantian and Dameisha, and a school's public exam strategy and student university admissions. It appears to be a highly disorganized and partially irrelevant advertisement disguised as financial news.

JAN 22·Investing.com

Exicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics

Exicure (NASDAQ:XCUR) has achieved a key milestone by completing its Phase 2 clinical trial for a novel stem cell mobilizer, NCT05561751, under its License and Collaboration Agreement with GPCR Therapeutics Inc. This achievement triggers a $1 million milestone payment to GPCR Therapeutics, which Exicure intends to fulfill. The company, valued at $41 million, also recently reported positive results from a separate Phase 2 trial for burixafor in multiple myeloma patients and fully redeemed convertible bonds using internal cash.

News on $XCUR

All news →